Analyst Price Target is $52.60
▲ +254.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for AbCellera Biologics in the last 3 months. The average price target is $52.60, with a high forecast of $59.00 and a low forecast of $45.00. The average price target represents a 254.21% upside from the last price of $14.85.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in AbCellera Biologics.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.